Table 2.
Univariate and multivariate Cox regression analysis for overall survival
| Risk factors | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p | HR | 95% CI | p | |
| Age > 60 years | 1.34 | 0.83–2.14 | 0.230 | – | – | – |
| Male sex | 0.96 | 0.57–1.61 | 0.887 | – | – | – |
| Smoking£ | 1.06 | 0.55–2.03 | 0.858 | – | – | – |
| ECOG-PS ≥ 1 | 1.74 | 1.08–2.79 | 0.023 | 1.64 | 1.01–2.65 | 0.045 |
| Primary tumor location | ||||||
| Larynx | 0.47 | 0.27–0.80 | 0.006 | 0.53 | 0.31–0.92 | 0.024 |
| Oral cavity | 1.74 | 1.06–2.86 | 0.028 | – | – | – |
| Pharynx | 1.23 | 0.73–2.08 | 0.426 | – | – | – |
| Others | 1.12 | 0.51–2.46 | 0.769 | – | – | – |
| p16 positivity* | 0.39 | 0.16–0.96 | 0.040 | – | – | – |
| PD-L1 positivity& | 0.72 | 0.27–1.91 | 0.724 | – | – | – |
| Metastasis sites | – | – | – | |||
| Lung | 0.77 | 0.48–1.23 | 0.273 | |||
| Bone | 0.73 | 0.40–1.31 | 0.285 | |||
| Soft tissue | 1.10 | 0.61–1.98 | 0.758 | |||
| Liver | 1.24 | 0.66–2.31 | 0.504 | |||
| Brain | 0.36 | 0.05–2.58 | 0.307 | |||
| Others | 0.61 | 0.24–1.51 | 0.285 | |||
| Previous treatments | – | – | – | |||
| Chemoradiation | 1.08 | 0.64–1.84 | 0.767 | |||
| Surgery | 1.26 | 0.79–2.03 | 0.326 | |||
| Adjuvant | 1.17 | 0.72–1.88 | 0.522 | |||
| Induction | 0.96 | 0.57–1.62 | 0.885 | |||
| No. of previous lines | ||||||
| 2 (as per 1) | 0.84 | 0.48–1.48 | 0.557 | – | – | – |
| ≥ 3 (as per 1) | 0.78 | 0.44–1.39 | 0.393 | |||
| Nivolumab dose ≥ 200 mg | 0.90 | 0.55–1.47 | 0.681 | – | – | – |
| Cycle interval of 21 days | 0.99 | 0.92–1.09 | 0.975 | – | – | – |
| Concomitant RT | 0.74 | 0.40–1.37 | 0.343 | – | – | – |
| NLR > 3.5 | 1.99 | 1.22–3.25 | 0.006 | 1.97 | 1.20–3.22 | 0.007 |
CI confidence interval, ECOG-PS Eastern Cooperative Oncology Group-Performance Status, HR hazard ratio, NLR neutrophil-to-lymphocyte ratio, RT radiotherapy
Out of £98, *55, and &33 patients
Bold text indicates statistical significance at p < 0.05